Related Experiment Video
Updated: Jun 28, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Oncotherapy resistance explained by Darwinian and Lamarckian models
Leukemia cells resistant to CD19 CAR-T therapy show reduced CD19 and CD22 expression. These cells are sensitive to targeted kinase inhibition, suggesting epigenetic changes drive resistance.
Area of Science:
- Immunology
- Oncology
- Epigenetics
Background:
- CD19-targeted therapies, like CD19 CAR-T cells, are standard treatments for B cell malignancies.
- High early relapse rates persist despite current therapies, indicating mechanisms of resistance.
Purpose of the Study:
- To investigate the mechanisms of resistance in B cell malignancies following CD19-targeted therapy.
- To identify potential therapeutic vulnerabilities in resistant leukemia cells.
Main Methods:
- Analysis of leukemia cells from patients relapsing after CD19-targeted therapy.
- Assessment of cell surface marker expression (CD19, CD22).
- Evaluation of sensitivity to Bruton's tyrosine kinase (BTK) and MEK inhibitors.
Main Results:
- Leukemia cells resisting CD19-targeted therapy exhibited reduced CD19 and low CD22 expression.
- These resistant cells demonstrated sensitivity to BTK and/or MEK inhibition.
- Resistance mechanisms appear to involve Lamarckian inheritance of epigenetic changes.
Conclusions:
- Epigenetic alterations play a crucial role in the evolution of resistance to CD19-targeted therapies.
- Targeting BTK and MEK offers a potential strategy for overcoming or preventing resistance.
- Predictable, epigenetic resistance mechanisms provide opportunities for novel therapeutic interventions.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Related Concept Videos
Treatment Resistant Cancers
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancers Originate from Somatic Mutations in a Single Cell
Targeted Cancer Therapies
There are several types of targeted therapies against...